Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6807094

CCCNC(=O)OC(C)(C)C.N

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.58
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
GAA P10253 1/20 0.55
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
CA12 O43570 5/20 0.47
CA1 P00915 5/20 0.47
CA2 P00918 4/20 0.47
CA9 Q16790 4/20 0.47
EPHX1 P07099 1/20 0.47
CA7 P43166 1/20 0.44
CA14 Q9ULX7 1/20 0.44
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4C Q9H3R0 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GFER P55789 1/20 0.42
CTSK P43235 2/20 0.41
CTSS P25774 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5973455 0.98 TDP1 (0.56) TDP1MEN1KMT2AGAAMAOA
SCHEMBL61208 0.98 TDP1 (0.60) TDP1MEN1KMT2AGAAMAOA
Hydrochloric Acid SCHEMBL28763000 0.96 TDP1 (0.58) TDP1MEN1KMT2AGAAMAOA
Bromide SCHEMBL28241790 0.96 TDP1 (0.58) TDP1MEN1KMT2AGAAMAOA
Hydrochloric Acid SCHEMBL27646037 0.96 TDP1 (0.58) TDP1MEN1KMT2AGAAMAOA
SCHEMBL7549979 0.90 TDP1 (0.58) TDP1MEN1KMT2AGAAMAOA
SCHEMBL27926441 0.88 TDP1 (0.51) TDP1MEN1KMT2AGAAMAOA
SCHEMBL7242914 0.88 TDP1 (0.51) TDP1MEN1KMT2AGAAMAOA
Ammonia Solution, Strong SCHEMBL4940325 0.88 TDP1 (0.65) TDP1MEN1KMT2AGAAMAOA
SCHEMBL15244383 0.87 TDP1 (0.50) TDP1MEN1KMT2AGAAMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951044-B2 Quinazoline derivatives and their use as DNA methyltransferase inhibitors PIERRE FABRE MEDICAMENT (FR) 2018-04-24 US disclosed
US-20170334948-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV NOVALIX DEUTSCHLAND GMBH (DE) 2017-11-23 US disclosed
EP-3046917-B1 QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS PF MEDICAMENT (FR) 2017-11-08 EP disclosed
US-9745339-B2 Ligands for antibody and Fc-fusion protein purification by affinity chromotography IV NOVALIX DEUTSCHLAND GMBH (DE) 2017-08-29 US disclosed
US-20160229834-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2016-08-11 US disclosed
EP-3046917-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS Pierre Fabre Médicament (FR) 2016-07-27 EP disclosed
US-20160009760-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV GRAFFINITY PHARMACEUTICALS GMBH (DE) 2016-01-14 US disclosed
WO-2015040169-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2015-03-26 WO disclosed
CN-1495184-A Substituted purine derivative, its preparation method, application and composition containing it �ճ�˹�عɷݹ�˾ 2004-05-12 CN disclosed
US-6723727-B1 VITRONECTIN RECEPTOR ANTAGONISTS; INHIBITORS OF BONE RESORPTION; OSTEOPOROSIS HOECHST AKTIENGESELLSCHAFT (DE) 2004-04-20 US disclosed
CN-1101816-C Substituted purine derivatives, their preparation, their use and compositions containing them HOECHST AG (DE) 2003-02-19 CN disclosed
CN-1193623-A Substituted purine derivatives, their preparation, their use and compositions containing them HOECHST AG (DE) 1998-09-23 CN disclosed
US-5668290-A CEPHALOSPORIN DERIVATIVES AS BACTERICIDES FOR GRAMPOSITIVE BACTERIA RESISTANT TO METHICILLIN BRISTOL-MYERS SQUIBB COMPANY (US) 1997-09-16 US disclosed
US-5620969-A BACTERICIDES BRISTOL-MYERS SQUIBB COMPANY (US) 1997-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334948-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV FCGR1A, FCGR2A, FCGR3B TDP1 4083/4885MEN1 2366/4885KMT2A 2665/4885
US-20160009760-A1 LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV FCGR1A, FCGR2A, FCGR3B TDP1 4135/4885MEN1 2594/4885KMT2A 2637/4885
US-20160229834-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS DNMT1, DNMT3A, TPMT TDP1 55/4885MEN1 1375/4885KMT2A 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.